Biopharma AI
ByIs Karyon Bio Using AI to Decode Disease Networks as Biopharma Moves Beyond Single-Target Drug Discovery?
Strategic Overview Karyon Bio is emerging as a next-generation AI-driven biotech focused on one of the industry’s most…
Is AION Labs Redefining AI Drug Discovery by Incubating Pharma-Native Startups from the Inside Out?
Strategic Overview AION Labs represents a structurally different model in the AI–biopharma landscape: a venture studio co-created by…
Is Ignota Labs Turning Pharma’s Failed Assets into a New AI-Driven Value Class?
Strategic Overview Ignota Labs is taking a fundamentally different approach to AI in biopharma—one that focuses not on…
Is XtalPi Emerging as Pharma’s AI Engine for Molecular Property Prediction and Manufacturability at Scale?
Strategic Overview XtalPi is carving out a differentiated position in the AI-biopharma landscape by focusing on one of…
Lantern Pharma Secures FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas, Expanding AI-Driven Precision Oncology Strategy
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
Can Insilico Medicine’s Hong Kong IPO Signal a Turning Point for AI-Driven Drug Discovery in Global Capital Markets?
Hong Kong | January 4, 2026 Insilico Medicine, a China-based, AI-driven drug discovery company backed by Qiming Venture…
